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Summary
Objective: Age-related changes in articular cartilage are likely to play a role in the etiology of osteoarthritis (OA). One of the major changes in
the extracellular matrix of cartilage is the age-related accumulation of advanced glycation end products (AGEs). Pentosidine, an AGE cross-
link, is one of the few characterized AGEs and is considered an adequate marker for the many AGEs that are formed in vivo. We used data
from a longitudinal observation study to determine if urinary pentosidine could serve as a marker to predict cartilage loss.
Methods: We conducted a prospective analysis of data from the Boston Osteoarthritis of the Knee Study (BOKS); a completed natural history
study of knee OA. All subjects in the study met American College of Rheumatology (ACR) criteria for knee OA. Knee magnetic resonance
(MR) images were scored for cartilage in 14 plates of the knee using the Whole Organ Magnetic Resonance Imaging Score (WORMS) semi-
quantitative grading scheme. Within the BOKS population, a nested sample of 127 subjects (39% of the whole sample) who had both baseline
pentosidine and longitudinal magnetic resonance imaging (MRI) measurements (MRIs performed at baseline and 30 months later) was as-
sessed. Urinary pentosidine was assayed and normalized to creatinine to account for differences in urine concentrations. We analyzed the
data using three different methods to assess if baseline measures of pentosidine predicted subsequent cartilage loss on MRI. These were
(1) analysis 1: logistic regression with the outcome cartilage loss in any plate; (2) analysis 2: proportional odds model where the outcome
was deﬁned as 0¼ no cartilage loss, 1¼ cartilage loss in one plate, 2¼ cartilage loss in two plates, and 3¼ cartilage loss in at least three
plates; and (3) analysis 3: Poisson regression with the outcome the number of plates with cartilage loss. All analyses were adjusted for
age, sex and Body Mass Index (BMI).
Results: At baseline the mean (standard deviation) age was 67 (9) years and 54% were male. The results for the three analytic steps are as
follows: Analysis 1: the odds ratio for cartilage loss is 1.01 (95% conﬁdence interval (CI) 0.93e1.09) with 1 unit increase in pentosidine. Anal-
ysis 2: the odds ratio for more cartilage loss is 0.99 (95% CI 0.92e1.06) with 1 unit increase in pentosidine. Analysis 3: the relative number of
plates with cartilage loss decreased was 1.00 (95% CI 0.95e1.03) with a 1 unit increase in pentosidine.
Conclusion: Urinary pentosidine does not predict knee cartilage loss. Previous studies have suggested that local content within cartilage of
AGEs is elevated in persons at high risk for progression. Our data suggest that these changes are not measurable systemically. Alternatively,
urinary pentosidine levels reﬂect cartilage degradation in all joints (thus whole body cartilage breakdown) and may therefore not relate to OA
severity in a single knee joint.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The last decade has seen assays developed which permit
the quantiﬁcation of collagenous and noncollagenous mac-
romolecules derived from bone, cartilage, and synovial tis-
sues1. This development has greatly enriched knowledge
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Received 14 March 2006; revision accepted 17 June 2006.93of matrix composition and metabolism of connective tissues
as well as of the underlying pathophysiologic processes in-
volved in disturbances of cartilage turnover.
The ability to use biochemical markers to predict disease
progression and identify patients most likely to progress is
a top priority in the future management of osteoarthritis
(OA). Ultimately, it would enable much more rapid assess-
ment of structure-modifying therapies in clinical trials. It may
also allow the identiﬁcation of persons at highest risk of pro-
gression, allowing the efﬁcient testing of new treatments.
Although its role in the pathophysiology of disease is not
fully understood, aging is one of the main risk factors for
the development of OA. Age-related changes in articular car-
tilage are therefore likely to play a role in the etiology of OA.
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lage is the age-related accumulation of advanced glycation
end products (AGEs). AGEs result from nonenzymatic glyca-
tion: the spontaneous reaction of a reducing sugar with pro-
teins2. Consequently, AGEs accumulate in all tissues with
age, but this accumulation is most pronounced in tissues
with long-lived proteins3. Articular cartilage is a tissue with
relatively low turnover and therefore contains high AGE
levels when compared with other tissues3,4. Pentosidine,
an AGE crosslink that is relatively straightforward to mea-
sure, is one of the few characterized AGEs and is considered
a good marker for the many AGEs formed in vivo5e7. Pento-
sidine levels in articular cartilage increase as much as
50-fold from age 20 to 808. This increase in AGE levels coin-
cides with the age-related increase in the incidence of OA,
suggesting that accumulation of AGEs may be involved
development of the disease.
Accumulation of AGEs in cartilage affects the biomechan-
ical, biochemical and cellular characteristics of the
tissue4,9e12 potentially making cartilage vulnerable to
loading and increasing the risk for damage. In addition to
measuring AGEs in cartilage, pentosidine can also be
measured in synovial ﬂuid, serum and urine13. To date, how-
ever, no study in humans has investigated whether urinary
pentosidine predicts cartilage loss on magnetic resonance
imaging (MRI). We took advantage of a natural history study
of symptomatic OA to investigate whether higher levels of
AGEs are associatedwith an increased risk for cartilage loss.
Materials and methods
STUDY SAMPLE
We conducted a prospective analysis of data from the
Boston Osteoarthritis of the Knee Study (BOKS); a com-
pleted natural history study of knee OA14. To be eligible
for the study, a person had to have knee pain, aching or
stiffness on most days within the last month, and they had
to have reported that a physician had told them that they
had arthritis in the knee. If they met both of those criteria,
then they underwent radiography (weight bearing ﬂuoro-
scopic PA, lateral and skyline views) and if, on any of these
views they had a deﬁnite osteophyte in the symptomatic
knee, they were eligible for the study. In addition, if they
screened positive for another form of arthritis or were using
medications that were appropriate for rheumatoid or other
forms of arthritis, they were excluded. Thus, all subjects in
the study had primary clinical knee OA and met American
College of Rheumatology (ACR) criteria for this disorder.
Of 324 subjects who entered the study, 86% completed
a full comprehensive follow-up at a later time-point (either
15 and/or 30 months). Those lost to follow-up did not differ
substantially from the other participants in age, or weight,
but were more likely to be men and to have higher WOMAC
pain and disability scores at baseline14. The comprehensive
examinations performed at each visit consisted of an MRI of
the more affected knee, and a comprehensive set of radio-
graphs including a semi-ﬂexed ﬂuoroscopically positioned
PA radiograph using the method of Chaisson et al.15 and
Buckland-Wright16.
This study was a nested sample selected from partici-
pants who had longitudinal MRI. Within the BOKS popula-
tion we selected approximately equal numbers of subjects
with cartilage loss and subjects without cartilage loss for
the purposes of the nested case control study. Assays
were conducted on this nested sample. The study was pow-
ered based upon a previous published study (OA andCOMP)17, where the mean score of COMP (log transformed
value) was 7.08 with standard deviation (SD) of 0.40 among
subjects with grades 3, 4 OA, and 6.91 with SD of 0.33
among subjects without OA. We assumed that the
difference in biochemical markers between subjects with
cartilage loss deﬁned by MRI and subjects without
cartilage loss is the same as that detected by radiographs.
With 70 subjects in each group and two-sided type I error be-
ing 0.05, the study had 90% power to detect the difference in
the mean value of COMP of 0.17 (an effect size of 0.42).
Urine (second morning void) specimens were also ob-
tained at baseline. Specimens were aliquoted and immedi-
ately frozen at 20(C. The specimens were stored at the
Biomedical Research Institute in Rockville, MD.
The institutional review boards of Boston University
Medical Center and the Veterans Administration Boston
Health Care System approved the baseline and follow-up
examinations.
MAGNETIC RESONANCE IMAGING
All studies were performed with a Signa 1.5 T MRI sys-
tem (General Electric Corp., Milwaukee, WI) using
a phased-array knee coil. A positioning device was used
to ensure uniformity of positioning among patients. The im-
aging protocol included sagittal spin-echo proton density-
and T2-weighted images (repetition time (TR), 2200 ms;
time to echo (TE) 20/80 ms) with a slice thickness of
3 mm, a 1-mm interslice gap, one excitation, a ﬁeld of
view (FOV) of 11e12 cm, and a matrix of 256 192 pixels;
and coronal and axial spin-echo fat-suppressed proton den-
sity- and T2-weighted images (TR 2200 ms; TE 20/80) with
a slice thickness of 3 mm, a 1-mm interslice gap, one exci-
tation, and with the same FOV and matrix.
Tibiofemoral (TF) cartilage on MRI was scored paired and
unblinded to sequence on 14 plates (anterior, central and
posterior femur; anterior, central and posterior tibia; medial
and lateral patella), using the Whole Organ Magnetic Reso-
nance Imaging Score (WORMS) semiquantitative method18.
Both cartilage signal and morphology were scored using
a 0e6 scale: 0¼ normal thickness and signal; 1¼ normal
thickness but increased signal on T2-weighted images;
2¼ solitary focal defect of less than 1 cm in greatest width;
3¼ areas of partial-thickness defects (<75% of the plate)
with areas of preserved thickness; 4¼ diffuse partial-thick-
ness loss of cartilage (75% of the plate); 5¼ areas of
full-thickness loss (<75% of the plate) with areas of par-
tial-thickness loss; 6¼ diffuse full-thickness loss (75% of
the plate). Intraobserver intraclass correlation coefﬁcient
on agreement for cartilage readings ranged from 0.75 to
0.97. The interobserver agreement was 0.62. Reliability
was based upon a random sample of 10 ﬁlms. Films were
read paired and unblinded to sequence by two readers
(AG, MG (see Acknowledgments) who are both musculo-
skeletal radiologists) using MRI sequence data from the sag-
ittal and coronal places.
In WORMS, grade 1 does not represent a morphologic
abnormality but rather a change in signal in cartilage of oth-
erwise normal morphology. Grades 2 and 3 represent sim-
ilar types of abnormality of the cartilage, focal defects
without overall thinning. Therefore, to create a consistent
and logical scale for evaluation of cartilage morphologic
change, we collapsed the WORMS cartilage score to
a 0e4 scale, where the original WORMS scores of 0 and
1 were collapsed to 0, the original scores of 2 and 3 were
collapsed to 1, and the original scores of 4, 5 and 6 were
considered 2, 3 and 4, respectively, in the new scale.
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plate compared to baseline.
We selected subjects who attended the baseline and ﬁnal
visits with an intervisit duration generally over 30 months.
Within the BOKS population, pentosidine and cartilage
loss on serial MRI were available on 127 participants.
Elevated blood sugar can potentially affect pentosidine
levels. We conducted additional analyses in the 111 sub-
jects without self-reported diabetes. The diagnosis of diabe-
tes was based upon self-report. The question asked ‘‘Do
you have diabetes (high blood sugar)?
PENTOSIDINE
Urinary pentosidine was measured by HPLC (Spark En-
durance autosampler and Dyonex P580 pump) in diluted
nonhydrolysed urine (1:1 in 0.025% H2SO4) following injec-
tion of 50 ml on a Whatman partisil 10 SCX column
(250 4.6 mm)19. Pentosidine was eluted using an iso-
cratic gradient of 0.025% H2SO4 and 100 mM Al2(SO4)3
in 0.025% H2SO4. Column temperature was kept at 60(C
and eluted pentosidine detected by a Jasco FP-1520 ﬂuo-
rimeter at 328 nm (ex) 378 nm (em). Puriﬁed pentosidine
calibrated by mass spectroscopy served as a reference.
Limit of detection: <2.4 pmol/ml, intra-assay variation:
5.6%, and interassay variation: 6.2%, with no freezee
thaw effects (pentosidine is stable, even upon acid hydroly-
sis at 110(C). Urinary pentosidine values were normalized
vs urinary creatinine to account for urinary dilution. No
degradation of pentosidine will occur in urine (nor in
serum), since the molecule is stable, even to overnight
110(C in 6 M HCl. Assays were conducted at TNO, The
Netherlands.
STATISTICAL ANALYSIS
We analyzed the data using three different methods to
assess if baseline measures of pentosidine predicted sub-
sequent cartilage loss on MRI (ascertained from baseline
to 30 month visit). These were (1) analysis 1: logistic regres-
sion with the outcome cartilage loss in any plate; (2) analy-
sis 2: proportional odds model where the outcome was
deﬁned as 0¼ no cartilage loss, 1¼ cartilage loss in one
plate, 2¼ cartilage loss in two plates, and 3¼ cartilage
loss in at least three plates; and (3) analysis 3: Poisson
regression with the outcome the number of plates with
cartilage loss. All analyses were adjusted for age, sex
and Body Mass Index (BMI).Results
At baseline the mean (SD) age was 67 (9) years and 54%
were male. The remainder of the demographic characteris-
tics are displayed in Table I. Seventy-six percent of the sub-
jects had radiographic TF OA (K&L 2), while the
remainder had patellofemoral OA. Further descriptive char-
acteristics for the participants are provided according to
whether they lost cartilage in any plate during the course
of 30 month follow-up or not. Compared to those that did
not lose cartilage at follow-up there was an overrepresenta-
tion of women and persons with PF OA (as opposed to TF
OA K&L 2) in participants who lost cartilage at follow-up.
There was no difference in pentosidine levels between the
two groups at baseline.
The results of analysis 1 (logistic regression with the out-
come cartilage loss in any plate) are displayed in Table II.
The unadjusted and adjusted odds ratios for cartilage loss
were 1.01 (95% conﬁdence interval (CI) 0.93e1.09) per 1
unit increase in pentosidine.
The results of analysis 2 (proportional odds model where
the outcome was deﬁned as 0¼ no cartilage loss,
1¼ cartilage loss in one plate, 2¼ cartilage loss in two
plates, and 3¼ cartilage loss in at least three plates) are
displayed in Table II. Both unadjusted and age, sex and
BMI adjusted odds ratios for cartilage loss was 0.99 (95%
CI 0.92e1.06) per 1 unit increase in pentosidine.
The results of analysis 3 (Poisson regression with the
outcome the number of plates with cartilage loss) are dis-
played in Table II. The relative number of plates with carti-
lage loss was 1.00 (95% CI 0.95e1.03) with 1 unit
increase in pentosidine. The results of the unadjusted anal-
yses are similar to those of the adjusted.
We restricted analyses to 111 subjects without self
ereported diabetes and found the results were similar.
Conclusion
Urinary pentosidine, an AGE crosslink does not predict
knee cartilage loss in subjects with symptomatic OA. Previ-
ous studies have suggested that the local content of AGEs
within cartilage is elevated in persons at high risk for pro-
gression. Our data suggest that these changes are not
measurable systemically.
Whilst the results of our ﬁndings may suggest that pento-
sidine does not predict cartilage loss, there are a number of
potential alternate explanations. Synovial ﬂuid is often rec-
ommended as the preferable body ﬂuid in which to analyzeTable I
Baseline characteristics of study population, N¼ 127
Whole
sample
No cartilage loss in any plate
(at follow-up), N¼ 59
Cartilage loss in any plate
(at follow-up), N¼ 68
Age, meanSD 67 9.05 67 7.97 68 9.94
Gender (male%) 54.33 57.63 51.47
BMI, meanSD 31 5.20 31 5.40 31 5.03
% K&L 2 76.19 66.10 85.07
History of knee joint injury (%) 44.4 47.5 41.8
Pentosidine/Cr, meanSD (mmol/ml) 1.85 4.66 1.91 4.96 1.80 4.42
Cartilage loss (no. of plates with cartilage loss).
Mean, range
1.02 (0, 5) e 1.91 (1, 5)
Median number of plates with cartilage loss (range) 1 (0, 5) e 1.91 (1, 5)
Proportion of participants with cartilage loss in one plate 25.20 e 47.06
Proportion of participants with cartilage loss in two plates 16.54 30.88
Proportion of participants with cartilage loss in three
or more plates
11.82 e 22.06
Proportion of subjects with diabetes 12.90 12.07 13.64
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Results of three analytic methods to determine if baseline measures of pentosidine predicted subsequent cartilage loss on MRI
Unadjusted OR (95% CI) Adjusted OR* (95% CI)
Analysis 1: logistic regression with the outcome of
cartilage loss in any plate
1.00 (0.92e1.07) 1.01 (0.93e1.09)
Analysis 2: proportional odds model for cartilage loss 0.99 (0.93e1.07) 0.99 (0.92e1.06)
Analysis 3: Poisson regression (relative risk) 1.00 (0.96e1.04) 1.00 (0.95e1.03)
*Adjusted for age, sex and BMI.biochemical markers, as serum and urine measurements
reﬂect systemic disturbances in turnover rather than local
pathological changes in OA joints. The urinary measure
was used as a less invasive and more available means to
obtain this marker level. It may be, however, that urinary
measurement of systemic pentosidine levels is not sufﬁ-
ciently sensitive to detect local alterations in AGEs in a sin-
gle joint. Urinary pentosidine is not highly correlated with
synovial ﬂuid or serum levels and thus our ﬁndings relate
speciﬁcally to urinary pentosidine measures only and fur-
ther work needs to be done on serum and or synovial ﬂuid
to ascertain if they predict OA progression13.
Previous studies of AGEs and pentosidine more speciﬁ-
cally have focused at the articular level. An alternate expla-
nation for our results is that urinary pentosidine levels may
reﬂect cartilage degradation in all joints (thus whole body
cartilage breakdown) and may therefore not relate to OA se-
verity in a single knee joint.
In addition, pentosidine is present in almost all connective
tissues. Its absolute level within a tissue primarily depends
on the turnover rate of that tissue. As was demonstrated by
Sell and Monnier20, the highest pentosidine levels are found
in dura mater and cartilage. But also meniscus, interverte-
bral disk, tendons, ligaments, skin and bone contribute to
excreted pentosidine levels. This causes the background
level above which a change due to elevated tissue destruc-
tion in the knee joint may rise. Based on our analyses we
may not be able to differentiate this change.
Previous studies on the accumulation of AGEs in carti-
lage have demonstrated that it affects the biomechanical,
biochemical and cellular characteristics of the tissue. At
the biomechanical level, increased AGE levels are accom-
panied by increased stiffness of the tissue9. Elevated AGE
levels not only increase tissue stiffness but also increase
cartilage brittleness, indicating that AGE accumulation
leads to increased susceptibility of articular cartilage to me-
chanical damage21. On the cellular level, accumulation of
AGEs was shown to decrease the synthesis of cartilage
proteoglycans4,10 and type II collagen12. In addition, degra-
dation of extracellular matrix constituents was impaired at
increased AGE levels11,12. In combination, the decreased
synthesis and degradation of the cartilage matrix result in
tissue that possesses decreased capacity to adapt to
changes in its environment (such as a different loading pat-
tern). Moreover, these data also suggest that decreased
cartilage turnover is likely to result in decreased repair ca-
pacity of the tissue. In combination these studies suggested
that the increased tissue brittleness and decreased extracel-
lular matrix turnover, due to the accumulation of AGEs,
resulted in an articular cartilage that was more prone to dam-
age, and by this mechanism, the age-related increase in car-
tilage AGEs could have explained the age-related increase
in the incidence of OA. These studies were not conducted
on systemic measures of AGEs such as pentosidine but
rather on tissue samples ex vivo.
A number of clinical studies have investigated the poten-
tial role of pentosidine in small clinical samples. Pavelkaet al.22 examined the prognostic value of different markers
for progression of knee OA. Eighty-nine persons with
knee OA and 20 healthy volunteers (not age matched) as
controls were examined. In persons with knee OA there
were higher serum levels of pentosidine compared with
healthy control subjects, and baseline pentosidine was cor-
related with further joint space narrowing. It is not clear if
any of the analyses are adjusted for age.
A cross-sectional study of 38 persons with knee OA and
38 healthy volunteers (again not age matched) were exam-
ined for serum and synovial ﬂuid concentrations of pentosi-
dine to determine whether there was a relationship with
cartilage oligomeric matrix protein23. Pentosidine in syno-
vial ﬂuid and in serum was correlated with synovial ﬂuid
COMP. Both pentosidine and COMP concentrations did
not correlate signiﬁcantly with the radiological stage of the
disease. Due to the differences in age between the OA
and healthy sample it is difﬁcult to know if the differences
found are due to age or disease.
Miyata et al.24 examined the concentrations of pentosidine
in plasma and synovial ﬂuid from 22 patients with
rheumatoid arthritis and compared their levels with those in
17 patients with OA, 26 diabetic patients, and 25 normal sub-
jects. Pentosidine levels in plasma and synovial ﬂuid fromRA
patients were signiﬁcantly higher than those in OA patients,
diabetic patients, and normal subjects. Chen et al.13 found
similarly that penotisidine levels in persons with rheumatoid
arthritis were considerably higher than those with OA.
There are some limitations of this work that warrant men-
tioning. Age-related increases are commonly seen in bio-
chemical markers and these may produce variation in both
AGE level and cartilage loss25. Efforts were made to adjust
for age in analyses. The BOKS study assessed the local
structural changes in participants knees only. For the pur-
poses of this study we investigated the knee that had an
MRI performed. It may be that other studies that investigate
the total body burden of OA including other joint areas such
as the hands, hips and spine or even the other knee may be
able to detect an association with urinary pentosidine.
Another potential explanation for our null ﬁndings is that
we have insufﬁcient power; given how null our ﬁndings are
this possibility is unlikely. The diagnosis of diabetes was
based upon self-report. Whilst self-report is likely to intro-
duce bias in classiﬁcation, particularly systematic underre-
porting the results of our analyses is unlikely to be any
different.
In sum, urinary pentosidine does not predict cartilage loss
in persons with symptomatic knee OA. Further work needs
to be done to explore if serum or synovial ﬂuid measures of
pentosidine predict cartilage loss.
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